Trial Profile
A randomised trial to compare the efficacy of ocaratuzumab and rituximab in patients presumed to have B-cell lymphoma with a low-affinity FcyRIII genotype.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 May 2012
Price :
$35
*
At a glance
- Drugs Ocaratuzumab (Primary) ; Rituximab
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Lpath; MENTRIK Biotech
- 02 May 2012 New trial record